Lexicon Pharmaceuticals, Inc.

Welcome to the Lexicon Pharmaceuticals Second Quarter 2026 Financial Results Conference Call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a brief question and answer session. As a reminder, this call is being recorded today, August 6, 2026. I will now turn the call over to Lisa DeFrancesco, SVP, Investor Relations, and Corporate Communications for Lexicon. Please go ahead, Lisa.

Thank you, Therese. Good morning and welcome to our second quarter 2026 earnings call. Joining me today are Dr. Mike Exton, Lexicon's Chief Executive Officer and Director, Dr. Craig Granowitz, Senior Vice President and Chief Medical Officer, and Scott Coiante, Senior Vice President and Chief Financial Officer. This morning, Lexicon issued a press release announcing our financial results for the second quarter of 2026 which is available on our website at www.lexpharma.com and through our SEC filings. A webcast of this call along with a slide presentation is also available on our website. During this call, we will review the information provided in our release, provide a corporate update, and then use the remainder of our time to answer your questions. Before we begin, let me remind you that we will be making forward-looking statements including statements relating to the safety, efficacy, clinical development, Regulatory Status and Therapeutic and Commercial Potential of Sotocliflozin, Pilvapidin, LX9851, and other drug programs, as well as our business generally. This call may also contain forward-looking statements relating to our growth and future operating results, discovery and development of our drug candidates, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. Various risks may cause our actual results to differ materially from those expressed or implied in such forward-looking statements, and we refer you to the most recent annual report on Form 10-K and other SEC filings for detailed information describing such risks. I would now like to turn the call over to Mike Exton. Mike?

Thank you, Lisa, and good day, everyone. Thanks for joining us. Look, I want to begin by focusing on our most recent and major accomplishments. The Completion of Enrolment in Sonata HCM, our Phase 3 Study of Soda Gaflosin in Hypertrophic Cardiomyopathy, or HCM. This study is the largest Phase 3 study to date in both obstructive and non-obstructive HCM. This marks an important milestone for patients living with the symptoms of HCM, as soda would be a completely novel and complementary treatment for their disease, as compared to all approved treatments currently available and other agents in development. We're thrilled with the outcome of our enrolment efforts, which resulted in the study being significantly over-enrolled. I couldn't be more pleased with the accomplishment of this critical milestone, and we eagerly await the top-line data which we expect to announce in Q1 of next year. In addition to the completion of enrolment in Sonata, we've also made other important progress across our portfolio. I'll start by providing an update on Venquista, where we're at an important and exciting moment for the program. If you recall, the FDA asked for three things to support a resubmission of our new drug application. A prospective study, adequate patient exposure, and GKA rates below those observed in our previous clinical trials. I'll ask Craig to take over here.